Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer.

Biomarkers in cancer Pub Date : 2015-08-18 eCollection Date: 2015-01-01 DOI:10.4137/BIC.S29716

Soley Bayraktar, Hongming Qiu, Diane Liu, Yu Shen, Angelica M Gutierrez-Barrera, Banu K Arun, Aysegul A Sahin

{"title":"Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer.","authors":"Soley Bayraktar, Hongming Qiu, Diane Liu, Yu Shen, Angelica M Gutierrez-Barrera, Banu K Arun, Aysegul A Sahin","doi":"10.4137/BIC.S29716","DOIUrl":null,"url":null,"abstract":"Background: Several studies have evaluated histologic features of non-neoplastic breast parenchyma in patients with BRCA1/2 mutations, but the results are conflicting. The limited data suggest a much higher prevalence of high-risk precursor lesions in BRCA carriers. Therefore, we designed this study to compare the clinicopathological characteristics of peritumoral benign breast tissue in patients with and without deleterious BRCA mutations.Methods: Women with breast cancer (BC) who were referred for genetic counseling and underwent BRCA genetic testing in 2010 and 2011 were included in the study.Results: Of the six benign histological features analyzed in this study, only stromal fibrosis grade 2/3 was found to be statistically different, with more BRCA noncarriers having stromal fibrosis grade 2/3 than BRCA1/2 carriers (P = 0.04).Conclusion: There is no significant association between mutation risk and the presence of benign histologic features of peritumoral breast parenchyma.","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":"7 ","pages":"39-49"},"PeriodicalIF":0.0000,"publicationDate":"2015-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541461/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4137/BIC.S29716","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Several studies have evaluated histologic features of non-neoplastic breast parenchyma in patients with BRCA1/2 mutations, but the results are conflicting. The limited data suggest a much higher prevalence of high-risk precursor lesions in BRCA carriers. Therefore, we designed this study to compare the clinicopathological characteristics of peritumoral benign breast tissue in patients with and without deleterious BRCA mutations.

Methods: Women with breast cancer (BC) who were referred for genetic counseling and underwent BRCA genetic testing in 2010 and 2011 were included in the study.

Results: Of the six benign histological features analyzed in this study, only stromal fibrosis grade 2/3 was found to be statistically different, with more BRCA noncarriers having stromal fibrosis grade 2/3 than BRCA1/2 carriers (P = 0.04).

Conclusion: There is no significant association between mutation risk and the presence of benign histologic features of peritumoral breast parenchyma.

Abstract Image

查看原文本刊更多论文

非肿瘤性乳腺实质的组织病理学特征无法预测浸润性乳腺癌患者的 BRCA 基因突变状态。

背景：多项研究对 BRCA1/2 基因突变患者非肿瘤性乳腺实质组织学特征进行了评估，但结果相互矛盾。有限的数据表明，BRCA 携带者的高危前驱病变发生率要高得多。因此，我们设计了这项研究，以比较有和无有害 BRCA 基因突变患者的瘤周良性乳腺组织的临床病理特征：方法：纳入 2010 年和 2011 年接受遗传咨询并接受 BRCA 基因检测的乳腺癌（BC）女性患者：结果：在本研究分析的六种良性组织学特征中，只有间质纤维化2/3级存在统计学差异，与BRCA1/2携带者相比，更多的BRCA非携带者患有间质纤维化2/3级（P = 0.04）：结论：突变风险与瘤周乳腺实质的良性组织学特征之间没有明显关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in cancer

自引率

0.00%

发文量